抗菌药物联合免疫球蛋白治疗中晚期肝病并发感染患者的临床效果

Clinical Efficacy of Antibacterial Drugs Combined with Immunoglobulin in the Treatment of Advanced Liver Disease Complicated with Infection

目的分析和对比中晚期肝病并发感染患者单用抗菌药物治疗及抗菌药物联合免疫球蛋白治疗的效果,为患者找到一种高效的治疗方案。方法选取我院收治的88例中晚期肝病并发感染患者作为本次研究主体,患者入院时间为2019年1~12月,入组后,采用单双号法对其进行分组,44例拿到单号者为对照组,44例拿到双号者为观察组,对照组采用抗菌药物治疗,观察组在对照组治疗方案基础上联合免疫球蛋白治疗,对比两组患者治疗前后的白细胞介素-6(IL-6)、C反应蛋白(CRP)等炎性因子水平以及T淋巴细胞(CD_(3)^(+))、辅助性T细胞(CD_(3)^(+))、细胞毒性T细胞(CD_(8)^(+))、辅助性T细胞/细胞毒性T细胞(CD_(4)^(+)/CD_(8)^(+))等免疫功能指标,对比两组治疗总有效率、并发症发生率。结果治疗前,两组患者IL-6、CRP等炎性因子水平及CD_(3)^(+)、CD_(4)^(+)、CD_(8)^(+)、CD_(4)^(+)/CD_(8)^(+)等免疫功能指标对比,差异无统计学意义(P>0.05);治疗后,观察组患者IL-6、CRP等炎性因子水平及CD_(8)^(+)均显著低于对照组,观察组患者CD_(3)^(+)、CD_(4)^(+)、CD_(4)^(+)/CD_(8)^(+)显著高于对照组,两组对比差异有统计学意义(P<0.05);对照组患者治疗总有效率45.45%显著低于观察组77.27%,两组对比差异有统计学意义(P<0.05);对照组患者并发症发生率31.82%显著高于观察组患者11.36%,两组对比差异有统计学意义(P<0.05)。结论在抗菌药物治疗的基础上增加免疫球蛋白对中晚期肝病并发感染患者治疗,不仅能有效减轻患者机体炎性因子水平,还能改善其免疫功能,降低并发症发生率。

Objective To analyze and compare the effects of antibiotics alone and antibiotics combined with immunoglobulin therapy in patients with advanced liver disease complicated by infection,and to find an efficient treatment plan for the patients.Methods A total of 88 patients with advanced liver disease complicated by infection in our hospital were selected as the subject of this study.The admission time range of the patients was from January 2019 to December 2019.After enrollment,they were divided into groups by odd and even numbers.The patients who got the odd number were the control group,and the 44 patients who got the double number were the observation group.The control group was treated with antibiotics,and the observation group was treated with immunoglobulin based on the treatment plan of the control group.The levels of inflammatory factors such as interleukin-6(IL-6)and C-reactive protein(CRP),as well as the levels of T lymphocytes(CD_(3)^(+)),helper T cells(CD_(3)^(+)),cytotoxic T cells(CD_(8)^(+)),helper T cells/the immune function indicators such as cytotoxic T cells(CD_(4)^(+)/CD_(8)^(+))were compared between the two groups.The total effective rate and the incidence of complications were compared.Results Before treatment,there was no significant difference in the levels of inflammatory factors such as IL-6 and CRP,and immune function indexes such as CD_(3)^(+),CD_(4)^(+),CD_(8)^(+),CD_(4)^(+)/CD_(8)^(+),etc.between the two groups(P>0.05).The levels of IL-6,CRP and other inflammatory factors and CD_(8)^(+) were significantly lower than those in the control group.CD_(3)^(+),CD_(4)^(+),CD_(4)^(+)/CD_(8)^(+) in the observation group were significantly higher than those in the control group,and the difference between the two groups was statistically significant(P<0.05).The total effective rate of treatment was 45.45%,which was significantly lower than that of the observation group,which was 77.27%,and the difference between the two groups was statistically significant(P<0.05).The incidence of complications in the observation group was 11.36%,which was lower than 31.82% in the control group,and the difference between the two groups was statistically significant(P<0.05).Conclusion The addition of immunoglobulin to the treatment of patients with advanced liver disease complicated by infection on the basis of antibiotic therapy can not only effectively reduce the level of inflammatory factors in the patient's body,but also improve their immune function and reduce the incidence of complications.